medigraphic.com
Instituto Nacional de Salud Pública

2020, Número 2

<< Anterior Siguiente >>

salud publica mex 2020; 62 (2)


Prevalencia de dislipidemias, diagnóstico previo, tratamiento y control: resultados de la Ensanut 2012

Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T, Rivera-Dommarco J, Hernández-Ávila M, Barquera S

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 137-146
Archivo PDF: 278.01 Kb.


RESUMEN

Objetivo. Describir en una muestra nacional 1) la prevalencia de dislipidemias, su diagnóstico previo, tratamiento y control, y 2) la prevalencia de dislipidemias en las encuestas previas. Material y métodos. Se analizaron datos de la Encuesta Nacional de Salud y Nutrición 2012 con representatividad nacional. Se analizaron fracciones de lípidos séricos de 9 566 adultos ≥20 años con ayuno ≥8 horas. Se estimaron las prevalencias de dislipidemias, diagnóstico previo (DP), tratamiento y control, ajustadas por edad. Se presenta un análisis comparativo de las prevalencias de dislipidemias reportadas previamente. Resultados. Las dislipidemias más prevalentes en adultos mexicanos fueron hipoalfalipoproteinemia y LDL-C elevado. Uno de cada cuatro adultos tenía hipercolesterolemia al momento de la entrevista, sin DP. El DP, tratamiento y control de dislipidemias fue de 12.6, 3.7 y 3.1%, respectivamente. Conclusiones. Las dislipidemias son el factor de riesgo para enfermedades cardiovasculares más prevalente en adultos mexicanos. Se necesitan políticas públicas para incrementar el diagnóstico, acceso a terapia y control.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Institute for Health Metrics and Evaluation. GBD Compare [Internet]. Seattle: IHME, 2015 [cited November 21, 2018]. Available from: http:// vizhub.healthdata.org/gbd-compare

  2. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol. 1993;22(4):A6-13. https:// doi.org/10.1016/0735-1097(93)90455-A

  3. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743-53. Available from: https://www.ahajournals.org/ doi/10.1161/CIRCULATIONAHA.107.699579

  4. Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, et al. Comparison of the framingham and reynolds risk scores for global cardiovascular risk prediction in the multiethnic women’s health initiative. Circulation. 2012;125(14):1748-56.

  5. Sahle BW, Owen AJ, Chin KL, Reid CM. Risk prediction models for incident heart failure: a systematic review of methodology and model performance. J Card Fail. 2017;23(9):680-7. https://doi.org/10.1016/j. cardfail.2017.03.005

  6. Lozano R, Gómez-Dantés H, Pelcastre B, Ruelas M, Montañez J, Campuzano J, et al. Carga de la enfermedad en México, 1990-2010. Nuevos resultados y desafíos [Internet]. Cuernavaca: Secretaría de Salud, Instituto Nacional de Salud Pública, 2014. Available from: https://www.insp.mx/ images/stories/Produccion/pdf/150122_cargaEnfermedad.pdf

  7. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol. 2004;13(3):125-38. https:// doi.org/10.1016/S1054-8807(04)00004-3

  8. Posadas-Romero C, Tapia-Conyer R, Lerman-Garber I, Zamora-González J, Cardoso-Saldaña G, Salvatierra-Izaba B, et al. Cholesterol levels and prevalence of hypercholesterolemia in a Mexican adult population. Atherosclerosis. 1995;118(2):275-84.

  9. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res [Internet]. 2001;42(8):1298-307. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 11483632

  10. Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, González C, et al. Dyslipidemias and obesity in Mexico. Salud Publica Mex. 2007;49(suppl 3):S338-47.

  11. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex [internet]. 2010;52 (suppl 1):S44-53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20585729

  12. Gutiérrez JP, Rivera-Dommarco JÁ, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales. Cuernavaca: Instituto Nacional de Salud Pública, 2013.

  13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem [Internet]. 1972;18(6):499-502. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4337382

  14. Stone NJ, Robinson JG, Lichtenstein AH, Bairey-Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol [Internet]. 2014;63(25):2889-934. Available from: https://linkinghub. elsevier.com/retrieve/pii/S0735109713060282

  15. Hernandez-Alcaraz C, Aguilar Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T, et al. Supplementary material. Dyslipidemia prevalence and trends. DRAFT VERS. Harvard Dataverse; 2019. p. 1-2. https://doi.org/10.7910/DVN/D3BA8V

  16. Goodman DS, Hulley SB, Clrak LT, Davis CE, Fuster V, LaRosa JC, et al. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med [Internet]. 1988;148(1):36-69. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte. 1988.00380010040006

  17. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying atherogenic lipoproteins: Current and future challenges in the era of personalized medicine and very low concentrations of ldl cholesterol. a consensus statement from EAS and EFLM. Clin Chem. 2018;64(7):1006-33.

  18. Rivera JA, Pedraza LS, Aburto TC, Batis C, Sánchez-Pimienta TG, González de Cosío T, et al. Overview of the dietary intakes of the mexican population: results from the National Health and Nutrition Survey 2012. J Nutr [Internet]. 2016;146(9):1851S-1855S. Available from: https://academic. oup.com/jn/article/146/9/1851S-1855S/4584848

  19. Lu Y, Wang P, Zhou T, Lu J, Spatz ES, Nasir K, et al. Comparison of prevalence, awareness, treatment, and control of cardiovascular risk factors in China and the United States. J Am Heart Assoc [Internet]. 2018;7(3):1-16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29374046

  20. Medina C, Janssen I, Campos I, Barquera S. Physical inactivity prevalence and trends among Mexican adults: results from the National Health and Nutrition Survey (ENSANUT) 2006 and 2012. BMC Public Health [Internet]. 2013;13(1):1063. Available from: http://bmcpublichealth.biomedcentral. com/articles/10.1186/1471-2458-13-1063

  21. Medina C, Tolentino-Mayo L, López-Ridaura R, Barquera S. Evidence of increasing sedentarism in Mexico City during the last decade: Sitting time prevalence, trends, and associations with obesity and diabetes. PLoS One. 2017;12(12):e0188518. https://doi.org/10.1371/journal.pone.0188518

  22. Berra K. Lipid-lowering therapy today. J Cardiovasc Nurs [Internet]. 2008;23(5):414-21. Available from: http://content.wkhealth.com/linkback/ openurl?sid=WKPTLP:landingpage&an=00005082-200809000-00007

  23. Schwiesow SJ, Nappi JM, Ragucci KR. Assessment of compliance with lipid guidelines in an Academic Medical Center. Ann Pharmacother [Internet]. 2006;40(1):27-31. Available from: http://journals.sagepub.com/ doi/10.1345/aph.1G303

  24. Zafrir B, Cohen S. Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Eur J Intern Med [Internet]. 2006;17(7):495-9. https://doi.org/10.1016/j.ejim.2006.03.005




2020     |     www.medigraphic.com